Neuraltus names Richard Casey president, CEO

Chutes and Ladders

Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.

Neuraltus names Richard Casey president, CEO

Neuraltus Pharmaceuticals has named Richard Casey president and CEO. Formerly chairman and CEO of Scios, Casey replaced Neuraltus' Interim CEO John Walker as head of the California biotech. At Scios--which was eventually sold to Johnson & Johnson ($JNJ) for $2.4 billion--Casey helped the company develop Natrecor for acute congestive heart failure. Neuraltus is working on several clinical-stage candidates to treat neurological disorders. Release

Neuraltus
Richard L. Casey will be the new president and CEO.


Tekmira
Bruce Cousins will serve as executive vice president and CFO.


Biotech

Tekmira Pharmaceuticals ($TKMR) has appointed Bruce Cousins as executive vice president and chief financial officer. Release

Michael Inouye has joined Omeros ($OMER) as vice president of commercial operations. He previously served as senior vice president of corporate and commercial development for Pharmacyclics ($PCYC) and senior vice president of commercial operations at Telik. Release

Glenn Killingworth joined PCI Synthesis as the company's new vice president of business development. Release

Cardio3 BioSciences appointed Gaëtane Metz as the company's new COO. Previously, Metz has served such companies as Altran Europe, CVO CyberConseil and GlaxoSmithKline ($GSK). Release

PHT named Andrea Valente its vice president of service delivery. Valente previously served as vice president of global services, education and customer support at OpenPages, which was acquired by IBM. Release

Michael Rogers joined Acorda Therapeutics as the company's chief financial officer, and David Lawrence has been appointed chief of business operations. Release

Neurotrope appointed Robert Weinstein as the company's executive vice president and chief financial officer. Weinstein has been the acting CFO as a consultant since May. Release

Gen9 appointed Christopher Bruce and Devin Leake as the company's vice president of global sales and vice president of research and development, respectively. Release

Voisin Consulting named Mark De Rosch as its vice president of regulatory drugs and biologics and head of U.S. operations, to be responsible for "providing strategic counsel to pharmaceutical and biotech companies with product and drug pipeline development globally." Release

Catharina Johansson will join NeuroVive Pharmaceutical as the company's new chief financial officer beginning in December. Release

Bay City Capital named Ashley Dombkowski as the company's managing director. Previously, she was the chief business officer and vice president of operations at 23andMe, the consumer genomics company. Release

Melinta Therapeutics has appointed Lyn Baranowski as senior vice president of corporate development and strategy. Release

CRO 

> Stephen Sullivan, founder of CRO Advisors, has joined the board of directors of PHT. Release

> John Davis has joined Selcia as director of discovery. Davis joins Selcia from Convergence Pharmaceuticals, where he was cofounder and also served as head of biology. Release

Pharma

Cynthia Smith has joined ZS Pharma as chief commercial officer. Previously, Smith served as vice president of market access and commercial development at Affymax ($AFFY). Release

Pharmagen brought on Confidence Ekeanyanwu as its quality-control manager. She has worked previously at NBTY as a microbiologist, as well as at Teva ($TEVA) and PepsiCo. Release

Biotech IT

> Instem has named Edward Lorenti as vice president of global sales. Prior to joining Instem, Lorenti was sales director at Accenture ($ACN). Release

> Optibrium has appointed Patrik Rydberg as associate director of computational chemistry to lead the company's contribution to the HeCaToS (Hepatic and Cardiac Toxicity Systems) project, a major European project that aims to investigate the health impact of compounds on the heart and liver. Release

Greenphire has appointed Alex Livingstone as senior director of business development in Europe. Livingstone previously served as global account manager at Phase Forward (now Oracle, $ORCL). Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.